{"prompt": "['Novartis', 'Confidential', 'Page 9', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', 'P-gp', 'P-glycoprotein', 'PASS', 'power analysis software', 'PCR', 'protein-creatinine ratio', 'PK', 'pharmacokinetic', 'PRO', 'patient-reported outcome', 'PT', 'prothrombin time', 'QMS', 'quality management system', 'QoL', 'quality of life', 'QTc', 'QT interval', 'QTcF', 'QT interval - Fridericia correction', 'RoW', 'rest of world', 'SABA', 'short-acting bronchodilator', 'SAE', 'serious adverse event', 'SAF', 'safety analysis set', 'sCr', 'serum creatinine', 'SCS', 'systemic corticosteroids', 'SD', 'standard deviation', 'SNOT-', 'sino-nasal outcome test - 22 questions', '22', 'SoC', 'standard of care', 'SOP', 'standard operating procedure', 'SUSARs', 'suspected unexpected serious adverse reactions', 'TBL', 'total bilirubin', 'Th2', 'T helper cell type 2', 'UK', 'United Kingdom', 'ULN', 'upper limit of normal', 'UPSIT', 'University of Pennsylvania smell identification test', 'US', 'United States', 'USB', 'universal serial bus', 'WHO', 'world health organization', 'WoC', 'withdrawal of consent']['Novartis', 'Confidential', 'Page 10', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', 'Glossary of terms', 'Assessment', 'A procedure used to generate data required by the study', 'Cohort', 'A specific group of subjects fulfilling certain criteria', 'Control drug', 'Any drug (an active drug or an inactive drug, such as a placebo) which is', 'used as a comparator to the investigational drug being tested in the trial', 'Dosage', 'Dose of the study treatment given to the subject in a time unit (e.g. 100 mg', 'once a day, 75 mg twice a day)', 'Enrollment', 'Point/time of subject entry into the study at which informed consent must be', 'obtained (i.e. prior to starting any of the procedures described in the protocol)', 'Epoch', 'Interval of time in the planned conduct of a study. An epoch is associated', 'with a purpose (e.g. screening, randomization, treatment, follow-up), which', 'applies across all arms of a study.', 'Investigational drug', 'The study drug whose properties are being tested in the study; this definition', 'is consistent with US CFR 21 Section 312.3 and Directive 2001/20/EC and is', 'synonymous with \"investigational new drug\" or \"test substance\"', 'Investigational', 'All investigational drug(s) whose properties are being tested in the study as', 'treatment', 'well as their associated treatment controls. This includes any placebos, any', 'active controls, as well as approved drugs used outside of their', 'indication/approved dosage or tested in a fixed combination. Investigational', 'treatment generally does not include other treatments administered as', 'concomitant background therapy required or allowed by the protocol when', 'used within approved indication/dosage.', 'Medication number', 'A unique identifier on the label of each study drug package in studies that', 'dispense study drug using an IRT system.', 'Non-investigational', 'Products which are not the object of investigation (e.g. any background', 'medicinal Product', 'therapy administered to each of the clinical trial subjects, regardless of', '(NIMP)', 'randomization group, rescue medication, active drug run-ins etc.)', 'Patient', 'An individual with the condition of interest', 'Period', 'A minor subdivision of the study timeline; divides phases into smaller', 'functional segments such as screening, baseline, titration, washout, etc.', 'Premature subject', 'Point/time when the subject exits from the study prior to the planned', 'withdrawal', 'completion of all study drug administration and assessments; at this time all', 'study drug administration is discontinued and no further assessments are', 'planned.', 'Randomization', 'A unique identifier assigned to each randomized subject, corresponding to a', 'number', 'specific treatment arm assignment', 'Screen Failure', 'A subject who is screened but is not treated or randomized', 'Stage', 'A major subdivision of the study timeline; begins and ends with major study', 'milestones such as enrollment, randomization, completion of treatment, etc.', 'Study completion', 'Point/time at which the subject came in for a final evaluation visit or when', 'study drug was discontinued whichever is later.', 'Study', 'Any drug (or combination of drugs) administered to the subject as part of the', 'drug/treatment', 'required study procedures; includes investigational drug, active drug run-ins', 'or background therapy.', 'Study treatment', 'Any drug administered to the study participants as part of the required study', 'procedures; includes investigational drug (s), control(s) or non-investigational', 'medicinal product(s)']\n\n###\n\n", "completion": "END"}